DUAL GIP AND GLP-1 RECEPTOR AGONISTS Market to Reach $1,570 Million by 2025

ASHBURNHAM, Mass. - Aug. 4, 2025 - PRLog -- DUAL GIP AND GLP-1 RECEPTOR AGONISTS Market to Reach $1,570 Million by 2025, Driven by Rising Demand in Diabetes and Obesity Treatment

Strong 11% CAGR Projected Through 2032 Amid Expanding Therapeutic Applications

The global DUAL GIP AND GLP-1 RECEPTOR AGONISTS market is projected to reach $1,570 million by 2025, driven by rising prevalence of type 2 diabetes and obesity, along with increasing clinical trials and drug approvals. The market is expected to grow at a compound annual growth rate (CAGR) of 11% from 2025 to 2032. North America and Europe are currently leading the market due to early adoption of novel therapies, while Asia-Pacific is emerging as a key growth region due to expanding healthcare infrastructure and increasing awareness.

Therapeutic applications in type 2 diabetes and chronic weight management are the primary drivers of demand for dual GIP and GLP-1 receptor agonists. These agents offer enhanced glycemic control and weight loss compared to single agonist therapies, making them attractive for healthcare providers and patients alike. In particular, combination therapies for metabolic syndrome and injectable formulations for long-term weight reduction are gaining significant traction.

In terms of pricing, the average cost of dual GIP and GLP-1 receptor agonist therapies rose by approximately 6% from 2024 to 2025, primarily due to increased R&D expenditures and limited competition. The United States saw the highest price hike due to high demand and regulatory hurdles, while Germany and Japan experienced moderate increases driven by reimbursement adjustments and rising raw material costs. However, future price stabilization is expected as biosimilar entrants and production scale-ups improve market efficiency.

Key players shaping the competitive landscape include Eli Lilly (U.S.), a frontrunner with its flagship drug tirzepatide, and Novo Nordisk (Denmark), which is actively expanding its GLP-1 portfolio with dual-acting candidates in development. In Asia, Hanmi Pharmaceutical (South Korea) and Innovent Biologics (China) are accelerating domestic innovation and partnerships to strengthen their foothold. Meanwhile, Pfizer (U.S.) and AstraZeneca (U.K.) are exploring pipeline collaborations and licensing deals to enter the market.

With ongoing advancements in peptide engineering, patient-centric delivery systems, and real-world evidence supporting clinical efficacy, the dual GIP and GLP-1 receptor agonists market is poised for sustained growth and strategic investment opportunities through 2032.

Request for customization https://datavagyanik.com/reports/dual-gip-and-glp-1-receptor-agonists-market/